Cardiac allograft survival in mice treated with IL-2-PE40. | Zendy

Haya LorberboumGalski | Zendy; Leslie V. Barrett | Zendy; Robert L. Kirkman | Zendy; M Ogata | Zendy; Mark C. Willingham | Zendy; David J. FitzGerald | Zendy; Ira Pastan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiac allograft survival in mice treated with IL-2-PE40.

Author(s) -

Haya LorberboumGalski,

Leslie V. Barrett,

Robert L. Kirkman,

M Ogata,

Mark C. Willingham,

David J. FitzGerald,

Ira Pastan

Publication year - 1989

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.86.3.1008

Subject(s) - pseudomonas exotoxin , fusion protein , cytotoxic t cell , exotoxin , biology , immunology , immunotoxin , receptor , cancer research , antibody , toxin , microbiology and biotechnology , monoclonal antibody , biochemistry , gene , recombinant dna , in vitro

IL-2-PE40 is a chimeric protein composed of human interleukin 2 (IL-2) genetically fused to the amino terminus of a modified form of Pseudomonas exotoxin lacking its cell recognition domain. IL-2-PE40, which is extremely cytotoxic to IL-2 receptor-positive cells, was examined for its ability to prevent graft rejection in mice in which activation of T cells is prominent. We demonstrate that intraperitoneally administered IL-2-PE40 specifically and significantly prolongs the survival of vascularized heart allografts in mice. The chimeric toxin, IL-2-PE40, offers an alternative approach to the treatment of autoimmune diseases and transplant rejection in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research